Sovaldi (Sofosbuvir) Patent Expiration, LOE Window & CMS Spending

Sovaldi (Sofosbuvir) by Gilead Sciences: FDA Orange Book core substance LOE 2031-06-11, 0 AB generics, $3.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN204671 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-06-11
Last Listed Patent or Exclusivity Date2031-06-11
Orange Book Patents (*PED Extensions)18 patents (9 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.5M
2024 Medicare Part D Spend$2.2M
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.